A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations containing alum increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection in mice

In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. prot...

Full description

Bibliographic Details

Main Authors:	Coria, Lorena M., Saposnik, Lucas M., Pueblas Castro, Celeste, Castro, Eliana Florencia, Bruno, Laura A., Stone, William B., Pérez, Paula S., Darriba, Maria Laura, Chemes, Lucia B., Alcain, Julieta, Mazzitelli, Ignacio, Varese, Augusto, Salvatori, Melina, Auguste, Albert J., Álvarez, Diego E., Pasquevich, Karina A., Cassataro, Juliana
Format:	info:ar-repo/semantics/artículo
Language:	Inglés
Published:	Frontiers Media 2024
Subjects:	Vaccine Adjuvants Proteinase Inhibitors Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Mice Coadyuvantes de Vacunas Inhibidores de Proteinasas Coronavirus del Síndrome Respiratorio Agudo Grave 2 Anticuerpos Ratón Germinal Center Cells Células del Centro Germinal
Online Access:	http://hdl.handle.net/20.500.12123/16609 https://www.frontiersin.org/articles/10.3389/fimmu.2022.844837/full https://doi.org/10.3389/fimmu.2022.844837